Changes in advanced oxidation protein products, advanced glycation end products, and s-nitrosylated proteins, in patients affected by polycythemia vera and essential thrombocythemia

Clinical Biochemistry

Volumn 45, Issue 16-17, 2012, Pages 1439-1443

  Musolino, Caterina ^a   Allegra, Alessandro ^a   Saija, Antonella ^a   Alonci, Andrea ^a   Russo, Sabina ^a   Spatari, Giovanna ^a   Penna, Giuseppa ^a   Gerace, Demetrio ^a   Cristani, Mariateresa ^a   David, Antonio ^a   Saitta, Salvatore ^a   Gangemi, Sebastiano ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b CNR   (Italy)

Author keywords

AGEs; AOPPs; Essential thrombocythemia; NGAL; Oxidative stress; Polycythemia vera; S Nitrosylated proteins; Thrombosis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT; CD11B ANTIGEN; HEMOGLOBIN; JANUS KINASE 2; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN; S NITROSYLATED PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; LEUKOCYTE ACTIVATION; MALE; NEUTROPHIL; NITROSYLATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN DEGRADATION; THROMBOCYTE ACTIVATION; THROMBOCYTHEMIA; THROMBOSIS;

ACUTE-PHASE PROTEINS; AGED; BLOOD PLATELETS; BLOOD PROTEINS; CASE-CONTROL STUDIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; JANUS KINASE 2; LIPOCALINS; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEUTROPHILS; NITROSO COMPOUNDS; OXIDATIVE STRESS; PLATELET ACTIVATION; POLYCYTHEMIA VERA; PROTO-ONCOGENE PROTEINS; SEQUENCE ANALYSIS, DNA; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84868303686     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.07.100     Document Type: Article

References (49)

1. Galli F., Piroddi M., Annetti C., Aisa C., Floridi E., Floridi A. Oxidative stress and reactive oxygen species. Contrib Nephrol 2005, 149:240-260.
2. England K., O'Driscoll C., Cotter T.G. Carbonylation of glycolytic proteins is a key response to drug-induced oxidative stress and apoptosis. Cell Death Differ 2004, 11:252-260.
3. Covacci V., Torsello A., Palozza P., Sgambato A., Romano G., Boninsegna A., et al. DNA oxidative damage during differentiation of HL-60 human promyelocytic leukemia cells. Chem Res Toxicol 2001, 14:1492-1497.
4. Shackelford R.E., Kaufmann W.K., Paules R.S. Oxidative stress and cell cycle checkpoint function. Free Radic Biol Med 2000, 28:1387-1404.
5. Singh R., Singh R.K., Mahdi A.A., Singh R.K., Kumar A., Tripathi A.K., et al. Circadian periodicity of plasma lipid peroxides and other anti-oxidants as putative markers in gynecological malignancies. In Vivo 2003, 17:593-600.
6. Singh R., Singh R.K., Tripathi A.K., Cornélissen G., Schwartzkopff O., Otsuka K., et al. Chronomics of circulating plasma lipid peroxides and anti-oxidant enzymes and other related molecules in cirrhosis of liver. Biomed Pharmacother 2005, 59:229-235.
7. Sun Y. Free radicals, antioxidant enzymes and carcinogenesis. Free Radic Biol Med 1990, 8:583-599.
8. Navarro J., Obrador E., Carretero J., Petschen I., Aviñó J., Perez P., et al. Changes in glutathione status and the antioxidant system in blood and in cancer cells associate with tumour growth in vivo. Free Radic Biol Med 1999, 26:410-418.
9. Danzig V., Míková B., Kuchynka P., Benáková H., Zima T., Kittnar O., et al. Levels of circulating biomarkers at rest and after exercise in coronary artery disease patients. Physiol Res 2010, 59:385-392.
10. Li Y., Liu S., Zhang Z., Xu Q., Xie F., Wang J., et al. RAGE Mediates Accelerated Diabetic Vein Graft Atherosclerosis Induced by Combined Mechanical Stress and AGEs via Synergistic ERK Activation. PLoS One 2012, 7:35016.
11. Lozovoy M.A., Simão A.N., Panis C., Rotter M.A., Reiche E.M., Morimoto H.K., et al. Oxidative stress is associated with liver damage, inflammatory status, and corticosteroid therapy in patients with systemic lupus erythematosus. Lupus 2011, 20:1250-1259.
12. Syngle A., Vohra K., Garg N., Kaur L., Chand P. Advanced glycation end-products inhibition improves endothelial dysfunction in rheumatoid arthritis. Int J Rheum Dis 2012, 15:45-55.
13. Marsche G., Frank S., Hrzenjak A., Holzer M., Dirnberger S., Wadsack C., et al. Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. Circ Res 2009, 27:750-757.
14. Del Turco S., Basta G. An update on advanced glycation endproducts and atherosclerosis. Biofactors Apr 10 2012, [Epub ahead of print]. 10.1002/biof.1018.
15. Anand P., Stamler J.S. Enzymatic mechanisms regulating protein S-nitrosylation: implications in health and disease. J Mol Med 2012, 90:233-244.
16. Abe R., Yamagishi S. AGE-RAGE system and carcinogenesis. Curr Pharm Des 2008, 14:940-945.
17. Foster M.W., Hess D.T., Stamler J.S. Protein S-nitrosylation in health and disease: a current perspective. Trends Mol Med 2009, 15:391-404.
18. Morabito F., Cristani M., Saija A., Stelitano C., Callea V., Tomaino A., et al. Lipid peroxidation and protein oxidation in patients affected by Hodgkin's lymphoma. Mediators Inflamm 2004, 13:381-383.
19. Gangemi S., Alonci A., Allegra A., Cristiani M., Russo S., Speciale A., Penna G., Spatari G., Cannavò A., Bellomo G., Musolino C. Studies on biomarkers for oxidative stress in patients with plasma cell disorders. Inflamm Res Jun 7 2012, [Electronic publication ahead of print].
20. Zhou F.L., Zhang W.G., Wei Y.C., Xu K.L., Hui L.Y., Wang X.S., et al. Involvement of oxidative stress in the relapse of acute myeloid leukemia. J Biol Chem 2010, 285:15010-15015.
21. Xu S., Venge P. Lipocalins as biochemical markers of disease. Biochim Biophys Acta 2000, 1482:298-307.
22. Gangemi S., Allegra A., Aguennouz M., Alonci A., Speciale A., Cannavò A., et al. Relationship between advanced oxidation protein products, advanced glycation end products, and S-nitrosylated proteins with biological risk and MDR-1 polymorphisms in patients affected by B-chronic lymphocytic leukemia. Cancer Invest 2012, 30:20-26.
23. Saville B. A scheme for the colorimetric determination of microgram amounts of thiols. Analyst 1958, 83:670-672.
24. Mitsumoto A., Kim K.R., Oshima G., Nakagawa Y. Chelation of cellular Cu(I) raised the degree of glyoxalase I inactivation in human endothelial cells upon exposure to S-nitrosoglutathione through stabilization of S-nitrosothiols. Biol Pharm Bull 2001, 24:336-341.
25. Marcondes A.M., Ramakrishnan A., Deeg H.J. Myeloid Malignancies and the Marrow Microenvironment: Some Recent Studies in Patients with MDS. Curr Cancer Ther Rev 2009, 5:310-313.
26. Ahmad R., Tripathi A.K., Tripathi P., Singh R., Singh S., Singh R.K. Studies on lipid peroxidation and nonenzymatic antioxidant status as indices of oxidative stress in patients with chronic myeloid leukaemia. Singapore Med J 2010, 51:110-115.
27. Singh R.K., Tripathi A.K., Tripathi P., Singh S., Singh R., Ahmad R. Studies on biomarkers for oxidative stress in patients with chronic myeloid leukemia. Hematol Oncol Stem Cell Ther 2009, 2:285-288.
28. Kim J.H., Chu S.C., Gramlich J.L., Pride Y.B., Babendreier E., Chauhan D., et al. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 2005, 105:1717-1723.
29. Sattler M., Griffin J.D. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 2003, 40:4-10.
30. Sattler M., Verma S., Shrikhande G., Byrne C.H., Pride Y.B., Winkler T., et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 2000, 275:24273-24278.
31. Gao Y., Howard A., Ban K., Chandra J. Oxidative Stress Promotes Transcriptional Up-regulation of Fyn in BCR-ABL1-expressing Cells. J Biol Chem 2009, 284:7114-7125.
32. Nowicki M.O., Falinski R., Koptyra M., Slupianek A., Stoklosa T., Gloc E., et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004, 104:3746-3753.
33. Koptyra M., Falinski R., Nowicki M.O., Stoklosa T., Majsterek I., Nieborowska-Skorska M., et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006, 108:319-327.
34. Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol 2003, 15:247-254.
35. Penserga E.T., Skorski T. Fusion tyrosine kinases: a result and cause of genomic instability. Oncogene 2007, 26:11-20.
36. Vener C., Novembrino C., Catena F.B., Fracchiolla N.S., Gianelli U., Savi F., et al. Oxidative stress is increased in primary and post-polycythemia vera myelofibrosis. Exp Hematol 2010, 38:1058-1065.
37. Sauer H., Wartenberg M., Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem 2001, 11:173-186.
38. Bigelow D.C., Squier T.C. Redox modulation of cellular signaling and metabolism through reversible oxidation of methionine sensors in calcium regulatory proteins. Biochem Biophys Acta 2005, 1703:121-134.
39. Hudson B.I., Kalea A.Z., Del Mar Arriero M., Harja E., Boulanger E., D'Agati V., et al. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem 2008, 283:34457-34468.
40. Azad N., Iyer A., Vallyathan V., Wang L., Castranova V., Stehlik C., et al. Role of oxidative/nitrosative stress-mediated Bcl-2 regulation in apoptosis and malignant transformation. Ann N Y Acad Sci 2010, 1203:1-6.
41. Guagnano M.T., Ferroni P., Santilli F., Paoletti V., Manigrasso M.R., Pescara L., et al. Determinants of platelet activation in hypertensives with microalbuminuria. Free Radic Biol Med 2009, 46:922-927.
42. Förstermann U. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch 2010, 459:923-939.
43. Yamagishi S., Matsui T., Takenaka K., Nakamura K., Takeuchi M., Inoue H. Pigment epithelium-derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs). Diabetes Metab Res Rev 2009, 25:266-271.
44. Yamagishi S.I. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol Nov 26 2010, [Epub ahead of print].
45. Kundranda M.N., Maiti B., Iqbal N. The association of leukocytosis, thrombocytosis and JAK2V617F mutation with thrombotic events in Myeloproliferative disorders (MPD's). Blood 2008, 112:2803. (Abs).
46. Arellano-Rodrigo E., Alvarez-Larran A., Reverter J.C., Villamor N., Colomer D., Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Hematol 2006, 91:169-175.
47. Allegra A., Alonci A., Bellomo G., Campo S., Cannavò A., Penna G., et al. Increased serum levels of Neutrophil gelatinase-associated lipocalin in patients with Essential Thrombocythemia and Polycythemia Vera. Leuk Lymphoma 2011, 52:101-107.
48. Roudkenar M.H., Halabian R., Ghasemipour Z., Roushandeh A.M., Rouhbakhsh M., Nekogoftar M., et al. Neutrophil gelatinase-associated lipocalin acts as a protective factor against H(2)O(2) toxicity. Arch Med Res 2008, 39:560-566.
49. Bahmani P., Halabian R., Rouhbakhsh M., Roushandeh A.M., Masroori N., Ebrahimi M., et al. Neutrophil gelatinase-associated lipocalin induces the expression of heme oxygenase-1 and superoxide dismutase 1, 2. Cell Stress Chaperones 2010, 15:395-403.